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Abstract
Radical surgical resection and adjuvant chemotherapy are the goal standard to attempt significant long term survival in
patients suffering from ductal pancreatic cancer. The role of extended lymph-node dissection is still a debated issue. In this
paper a deep review of the experiences reported in the literature is carried out. Several studies are limited, not randomized and
retrospective: generally speaking they seem to suggest a positive role in node dissection. Unfortunately, this trend is not
confirmed in the only two trials conducted in a prospective and randomized setting. Moreover the results of these studies are
also difficult to compare. At the moment we can say that extended lymphadenectomy does not play a determinant role for long
term survival but a positive trend has been shown for node positive patients.
The only realistic chance of a cure for patients suffering
from ductal pancreatic cancer of the pancreas is the
radical resection of the tumors.
In the past, the disappointing results achieved in the
overall long-term survival of resected patients appeared
to prompt many surgeons to refrain from surgical
intervention [1].
What we have actually witnessed over the years is a
progressive increase in resection rates, which have
steadily risen from around 20% some 15–20 years ago
to an average of 35% of cases observed today and which
now even exceed 50% in some centers [2]. Moreover
the tempting results on long-term survival rate recently
achieved by adjuvant treatment in a large multi-center
randomized study further support the need of aggres-
sive behaviour [3,4]. Today we believe that in cases in
which the preoperative staging has ruled out both
remote metastases and loco-regional, not resectability,
it is ethically mandatory to regard ‘taking it out’ (plus
adjuvant chemotherapy!) as the primary aim of cur-
ative treatment of carcinoma of the pancreas; this
seems to be the suggested and correct policy to use in
those centers where the morbidity (around 30%) and
mortality rates (55%) make this a feasible and
reasonable proposition.
The ‘N’ factor
Unfortunately the staging of the N factor can be
completely clarified only after surgical resection, and
the reliability of lymph-node negativity is directly
related to the extent of the performed lymphade-
nectomy and to the pathologist care in the specimen
analysis. Moreover, there is a frequent lack of corre-
lation between tumor diameter and lymph-node posi-
tivity, which, in some case series, may be present in as
many as 50% of cases of small tumors (T52 cm) [5].
The risk of false-negatives also results in the lack of
anatomical contiguity in the lymphatic invasion pattern
of the pancreatic cancer, with possible positivity in
remote lymph-node stations together with negative
peripancreatic lymph nodes. The result of this behavior
of N factor and the lack of any correlation between
N positivity and precise ‘evidence based’ adjuvant
options, is that the effective need for a more or less
extended lymphadenectomy accompanying the take-
out in carcinoma of the pancreas remains a hotly
debated issue.
Looking at the frequency and pattern of lymph-node
involvement in pancreatic cancer, it can be noted
that the rate of resected patients with lymph-node
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involvement is around 70% [1–41]. The more aggres-
sive approach adopted in Japan might be thought to
lead to a generally higher incidence of lymph-node
positivity in case series in the Far East. Surprisingly the
percentage distribution shows no significant difference
on the basis of this parameter: the figure reported by
the Japan Pancreas Society (74.6% positivity) [6] is
comparable to the rates reported in European [7] and
American [8] studies (67.5% and 71.6%, respectively).
In our own more recent series of 100 patients under-
going pancreaticoduodenoctomy for ductal carcinoma,
67 were lymph-node positive (unpublished data).
Particularly interesting, in this connection, are the
studies conducted by Cubilla and Fitzgerald [9], which
show that the standard Whipple successfully removes
80% of the lymph-node sites most commonly involved.
Apart from this study, the literature contains very few
reports of pathological analyses of surgical specimens
aimed at establishing the topographical distribution of
the lymph-node areas affected by the tumor spread
[5,10,11].
In this sector, the Japanese literature is by far the
most informative, thanks above all to Nagakawa’s
study [5], which was planned with the intention to
assess, on the basis of quantitative evidence, whether
lymphadenectomy should be also extended to the
remote lymph nodes: 68.6% of patients presented
lymph-node metastases, and 73.7% of these lymph-
node-positive subjects showed simultaneous positivity
of the resection margin of the posterior lamina. Also
looking at our already stressed most recent experience
on 100 consecutive patients, the rate of R1 and R2 with
N positivity is similar (67.5%). The lymph-node areas
most affected are similar too: area 13 (posterior to the
head of the pancreas), 17 (anterior to the head of the
pancreas) and 14 (radix of the mesenteric area),
followed by areas 12 (hepatoduodenal ligament) and
16 (along the abdominal aorta).
All other sites are only sporadically affected. In
particular, in area 16 the highest incidence is in the
interaortocaval region.
The extent of lymphatic metastasis tends to increase
with tumor diameter, though the finding in two of
Nagakawa’s cases [5] of small tumors (diameter
52 cm) which had already metastasized to area 16
provided evidence of a poor correlation with bizarre
involvement and distribution of the N factor as
compared to the T factor. This unpredictability is
further confirmed by our own experience: in a study
aimed at detecting small tumors of the pancreatic head
[12], none of the 4 cases prospectively identified out of
72 consecutive observations were N+. By contrast, 3
out of 7 small tumors identified retrospectively in 56
historical patients were N+; even one of the more
recent cases with lymph-node positivity had a diameter
of 1.5 cm. Taken together all these data would appear
to suggest that the pathway of para-aortic metastases
passes via a retroperitoneal lymphatic route from area
13 to area 14 before reaching area 16.
On the basis of his analysis, Nagakawa concludes
that ‘an extensive dissection including areas 14 and 16
is necessary for radical resection’ [5].
Non-performance of a standard lymphadenectomy
in all patients, in Western series, might be interpreted
as the result of both a non-homogeneous surgical
approach and definitions used for the standard and
extended procedures by the Western surgeons. In
actual fact, we surgeons often find ourselves having to
operate on patients who, despite the disease, present a
major intra-abdominal lipid component of a type
which, for anthropomorphic and dietetic reasons, is
comparatively rare in Eastern populations. This tech-
nical obstacle often proves insurmountable except by
prolonging the related operative times and risks, at
least in theoretical terms.
For this reason, our recent series included only 15
N+ cases potentially capable of providing data on the
ill-famed area 16. Two patients presented positivity in
this area, both of which in lymph nodes of inter-
aortocaval origin. The similarities to Nagakawa’s
findings [5], in terms of both frequency and site, are
suggestive.
In one of our two cases, sequential involvement of
areas 13? 14? 16 was observed, whereas in the other
the area 16 positivity coincided with positivity only of
area 13, all the other areas yielding negative findings.
The erratic pattern of lymph-node involvement is
also confirmed by two cases which were lymph-node
negative in area 13, but positive at the level of the
hepatoduodenal ligament (area 12): one of these
tumors had a diameter of 1.5 cm (the above-mentioned
small N+ tumor) and the other a diameter of 4 cm.
Despite these incongruities, which make any corre-
lation between N and T factors unreliable, in our case
series, too, the mean diameter of the N7 tumors was
less than that of the N+malignancies (26.3 mm, with
a range from 10 mm to 40 mm; and 30.5 mm, with a
range from 15 mm to 40, respectively).
The ‘N’ factor and the prognosis
Despite the generally widespread conviction that the
presence of lymph-node metastases is a highly pre-
judicial factor for the prognosis of pancreatic carci-
noma, this is by no means an established fact in the
literature [1–41]; several studies fail to tackle the issue
on the basis of multivariate-type analysis, leaving the
reader with the suspicion that some other co-factor
potentially capable of affecting the prognosis may to
some extent blur the real significance of lymph-node
positivity.
An elegant study by Cameron et al. [13] showed,
however, that, in multivariate analysis, too, the strong-
est predictive factor is lymph-node status with a
median survival of 55.8 months in N7 patients as
against 11 in N+ subjects. In 1995, the same group [8]
substantially confirmed the findings for lymph-node
status, associating it, additionally, with tumor diameter
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(43 cm) and the state of the resection margin, with
relative risks of 1.6, 1.7 and 1.4, respectively. In a sub-
population of patients who were also studied in terms
of tumor DNA status, however, aneuploidy was the
element with the highest relative risk (2.7), followed by
tumor diameter (2.2), lymph-node status (1.7) and
resection margin positivity (1.6).
We can therefore reasonably conclude that lymph-
node status is an independent factor capable of
affecting survival times in patients undergoing resec-
tion for pancreatic ductal carcinoma. The N factor also
appears to be decisive with regard to long-term survival
(beyond 5 years): in a recent study aimed at identifying
the characteristics of patients destined to survive for
longer periods [14], all the patients surviving for more
than 10 years were N7.
Finally, in the recent ESPAC trial, stratifying the use
of adjuvant chemotherapy according to the N status
did not affect the overall treatment result [3,4].
Results of extended versus traditional
lymphadenectomy
Because of the yet unclear pattern of lymph-node
involvement and its effective prognostic role in
pancreatic cancer, the value of systematic lymph-node
dissection is still a much debated issue; this refers to the
need, if any, for extending lymph-node removal after
pancreatic resection, which involves a proximal
lymphadenectomy in itself.
Lymphadenectomy in pancreatic cancer, contrary to
that in other tumors (breast, stomach and colon),
yields no indications of an adjuvant options based on
nodes positivity: the advocates of this ‘extended’
approach can do no more than base their rationale on
the intrinsic therapeutic efficacy as such (removal of
malignant foci and interruption of lymphatic spread).
In 1988, Isikawa et al. [15], in a limited number of
cases, showed a significant increase in survival. Naga-
kawa [16], however, stresses that, if we want to offer
the individual patient the maximum chance of survival,
we cannot confine ourselves to extended lymphade-
nectomy alone, but must also remove the retro-
peritoneal laminar tissue including the celiac nerve
plexus. The benefit in terms of survival is questioned by
the Japanese authors themselves as these patients are
liable to experience devastating diarrhea requiring
periods of long hospitalization [17].
By contrast, in Western countries few authors
suggest more radical approach than a standard resec-
tion [18,19]. The concept of ‘radical resection’ was
introduced by Fortner at the beginning of 70s [20] with
wide vascular removal; nowadays the term radical or
extended resection means wide soft tissue resection
and retroperitoneal lymphadenectomy. The ‘standard’
means to include anterior and posterior pancreatico-
duodenal, pyloric, main bile duct, superior and inferior
head and body nodes; the ‘extended’ means to include
at the already mentioned nodes stations the liver hilum
along the aorta from the diaphragmatic hiatus to the
inferior mesenteric artery, celiac trunk, superior
mesenteric artery and both renal hili [40].
Isikawa [15] showed a 3-year survival rate of 13%
versus 38% comparing standard versus radical resec-
tion in a historical and prospective group of 37 and 22
patients respectively. Also the retrospective Manabe
study involves patients not comparable for tumor
staging [21]; other reports got surprising morbility and
mortality rates [10,22].
The prospective non-randomized study by Henne-
Bruns [18] did not show any benefit of radical re-
section, with a general high mortality and without
inclusion of complete removal of hepatoduodenal and
celiac origin nodes.
The first prospective randomized study reported in
the literature comes from Italy by the Multicenter
Lymphadenectomy Study Group [23]. From March
1991 to March 1994, a total of 83 patients with cancer
of the head of the pancreas were recruited by 6
contributing centers.
Patients undergoing laparotomy were eligible to
enter the trial if the entire macroscopic tumor could be
excised. In the course of thorough surgical exploration,
the tumor diameter was evaluated and frozen sections
of peripancreatic nodes suspected of being metastatic
were obtained. Randomization was carried out during
laparotomy. If the study inclusion criteria were met,
patients were stratified as follows: the first stratum
included lymph-node-negative pancreatic tumors
measuring less than 4 cm in diameter, while the second
stratum comprised all lymph-node-positive pancreatic
tumors and node-negative tumors measuring more
than 4 cm in diameter.
Patients were then allocated to traditional or
extended lymphadenectomy. Classic Whipple or
pylorus-preserving pancreaticoduodenectomy were
performed on the basis of the operating surgeon’s
preference.
Traditional lymphadenectomy included resection of
the anterior and posterior pancreaticoduodenal, in-
ferior head, pyloric, common bile duct, superior
head, superior mesenteric and superior and inferior
pancreatic body nodes. In addition to the latter,
extended lymphadenectomy also entailed removal of
the hepatic duct, mid-colic, celiac axis and para-aortic
region nodes. Forty-two patients were randomized to
traditional and 41 to extended lymphadenectomy.
Histological specimens were reviewed by two inde-
pendent pathologists (G. Kloppel and K. Dhaene,
from Kiel). Two patients in the traditional lymphade-
nectomy group were subsequently excluded, one
because suffering from an endocrine tumor and the
other because of postoperatively histologically proven
liver metastasis. The characteristics of the two patient
groups were comparable for age, sex, length of follow-
up, tumor stage, tumor diameter and grading.
The number of lymph nodes removed with the
extended procedure was significantly greater than with
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the traditional one; no adjuvant treatment was given to
either group postoperatively.
The overall survival was the same in the two groups
(p50.05). Neither age, sex, surgical department,
pylorus-preserving procedures nor intra-operative
radiotherapy influenced survival. Worse survival was
observed in patients with high-grade tumors
(p=0.001), tumor diameters 42 cm (p=0.002) and
lymph-node metastases (p=0.006). Lymph-node-
positive patients had significantly better survival after
extended than after traditional lymphadenectomy
(p=0.026); moreover, survival was the same in N7
patients (whatever the type of lymphadenectomy) and
in N+ patients treated with an extensive approach.
The most recent prospective and randomized study
on the topic was published in 2000 by Yeo et al. [24]
who admitted 294 patients to the trial. Comparing
standard versus radical resection (the latter differs in
the extension of nodes dissection from other prospec-
tive studies [18,22]) there were no significant differ-
ences neither in 1-, 3- and 5-year survival (80% versus
77%, 44% versus 44% and 23% versus 29% respec-
tively) nor in median survival (30 versus 28 months).
These negative data on the role of extended nodes
resection in pancreatic cancer seem to be confirmed in
a still not published study coming from Majo Clinic
[25].
Last, a further concept of radical surgery includes
the segmental resection of the mesenteric-portal vein.
Also in this area the data coming from the literature are
conflicting and mainly derived from retrospective or
not randomized experiences [26–34].
Tables I, II and III report the main data on extended
versus standard surgery for pancreatic cancer coming
from retrospective, prospective non-randomized and
randomized studies respectively.
Looking at safety, there are no significant differences
in postoperative morbidity and mortality in the patient
groups undergoing classic lymphadenectomy as
compared to those undergoing the extended procedure
[21,23,26].
In our experience [23], both the number of trans-
fusion recipients and blood units used showed no
significant difference between the two treatment
groups; also the post-operative hospitalization was
comparable and, as regards operative times, extended
lymphadenectomy took on average about 30 min
longer to perform than the classic operation.
In the Yeo study [24] the final results [35] confirm
the similar mortality rate between extended and
standard procedures (2% and 4% respectively) but
increased morbidity in the radical resection, mainly
due to a higher rate of delayed gastric empting (16%
versus 6%) and pancreatic fistula (13% versus 6%).
Last but not least, in long-term survivors, no differ-
ences in quality of life have been reported in a very
recent study [36].
Conclusions
How meaningful, then, today is a lymphadenectomy
procedure involving a greater measure of radicality?
The only controlled data provided by two prospective,
randomized studies [23,24] would appear to suggest
that extended lymphadenectomy is not capable of
favorably affecting prognosis, at least in the population
of resected patients as a whole. Unfortunately, the
results of these two studies are difficult to compare and
both underpowered; because of the small difference in
Table I. Reports of standard versus extended surgery in pancreato-
dudodenectomy for pancreatic ductal cancer
Patients for
group (N) Mortality
5-year
survival (%)
Hartel* (29) 68 17 4.4
Keek* (30) 18 0 5.6 (3 years)
Klempnauer* (31) 38 13 15.8
Roder* (32) 31 0 0 (3 years)
Shibata* (33) 28 9 3.6
Takahashi* (34) 79 13 10.1
standard–
extended
standard–
extended
standard–
extended
Ishikawa (15) 37–22 5/37–1/22 9–28
Manabe (21) 42–32 4/42–2/32 –
Satake (41) 72–57 5/129–0/57 25 both
Sindelar (22) 20 4/20 10 both**
Study type: retrospective. *=extended venous resection. **=3-year
survival.
Table II. Reports of standard versus extended surgery in pancreato-
dudodenectomy for pancreatic ductal cancer
Patients for
group Mortality
5-year
survival (%)
Fuhrmann* (26) 36 2.8 n.d.
Harrison* (27) 58 10 5.2
Van Green* (28) 64 6 0 (3yrs)
standard–
extended
standard–
extended
standard–
extended
Cappussotti (39) 122–37 n.s. n.s.
Henne-Bruns (18) 26–46 1/26–3/46 35–17.6
Study type: prospective. Evidence level: non-randomized. *=
extended venous resection.
n.d., not determined.
n.s., not significant.
Table III. Reports of standard versus extended surgery in pancreato-
dudodenectomy for pancreatic ductal cancer
Patients for
group (N)
standard–
extended
Mortality
standard–
extended
5-year survival (%)
standard–
extended
Pedrazzoli (23) 40–41 2/40*–2/41* 7.4**
Yeo (24, 35) 146–148 6/146*–3/148* 10–25
Study type: prospective. Evidence level: randomised. *= non
significant. **= 4-year survival.
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survival rate between the two different procedures, in
order to detect a significant result, it should be neces-
sary to admit at least 1000 patients for an adequately
powered trial! All the others’ experiences are limited,
not randomized and mainly retrospective [1–41].
At the moment we can state that extended lympha-
denectomy does not play a determinant role for long-
term survival in pancreatic cancer, but a positive
tendency should be deserved for node positive patients
[23].
Preoperative recognition of positive nodes patients
and potentially R0 resections seem to be the up-to-
date clinical challenges together with the further
understanding of the role of adjuvant treatment
[3,4,37,38].
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